ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP announced an investigation into Alnylam Pharmaceuticals regarding potential federal securities law violations. The firm's inquiry relates to Alnylam's July 30 disclosure lowering FY2026 TTR sales guidance by roughly $200 million, which coincided with a 28% share price drop.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.